Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002
20200908 Transgene TG6002 Phase 1 EN
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
AACR2020-BT-001 Jean-Baptiste Marchand et al. AACR 2020 Download the poster [...]
Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects
AACR2020 6010 J. Foloppe et al. AACR 2020 Download the [...]
Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models
20200622b - BT-001_AACR poster EN
Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
20200622a - Transgene PR AACR 3 posters
Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors
20200515 BT-001_AACR curtain raiser EN
Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors
20191211 PR preclinical BT001 EN
Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming
Transgene SITC 2019 Poster Jean-Baptiste Marchand et al. SITC 2019 [...]
Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
20190326 PR BioInvent extension CDR US